Latest News on BCRX

Financial News Based On Company


Advertisement
Advertisement

Four parties report owning no shares in BioCryst (BCRX).

https://www.stocktitan.net/sec-filings/BCRX/schedule-13g-a-biocryst-pharmaceuticals-inc-amended-passive-investmen-d624a246fe13.html
An amended Schedule 13G filing reveals that RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. each report zero beneficial ownership in BioCryst Pharmaceuticals, Inc. (BCRX) as of September 30, 2026. This represents 0.0% of the class for each reporting person, with no sole or shared voting or dispositive power. The filing serves as a passive investment disclosure indicating no significant stake.

Understanding Momentum Shifts in (BCRX)

https://news.stocktradersdaily.com/news_release/81/Understanding_Momentum_Shifts_in_BCRX_111526065602_1794743762.html
This article analyzes Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX), highlighting divergent sentiment across trading horizons and elevated downside risk due to a lack of long-term support signals. It provides three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop levels for different risk profiles. The analysis also includes multi-timeframe signal analysis, identifying near-term neutral, mid-term weak, and long-term strong biases with corresponding support and resistance levels.

BioCryst Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $19.3, Implies 151% Upside

https://www.tradingview.com/news/tradingview:f7e164021624d:0-biocryst-pharmaceuticals-inc-stock-12-month-price-target-cut-to-19-3-implies-151-upside/
BioCryst Pharmaceuticals, Inc.'s average price target has been lowered from $20.45 to $19.3 by 10 analysts, with forecasts ranging from $11 to $30 per share. This updated target suggests a potential upside of approximately 151% based on the November 12 closing price. The consensus rating for the stock remains a "Buy," with 8 analysts recommending a Buy and 2 recommending a Hold.

BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting

https://www.globenewswire.com/news-release/2026/11/13/3402489/29446/en/biocryst-presents-new-real-world-evidence-showing-reduced-angioedema-related-medical-visits-after-switching-to-orladeyo-berotralstat-at-acaai-2026-annual-scientific-meeting.html
BioCryst Pharmaceuticals announced new real-world evidence demonstrating that its drug ORLADEYO (berotralstat) significantly reduced angioedema-related medical visits, hospitalizations, and emergency department visits in hereditary angioedema (HAE) patients. These findings, presented at the ACAAI 2026 Annual Scientific Meeting, highlight the clinical and economic benefits of ORLADEYO for both patients initiating long-term prophylactic therapy and those switching from other treatments. Two studies showed significant reductions in healthcare resource utilization, supporting ORLADEYO as an effective long-term prophylactic therapy for HAE.

Does Raised 2026 Guidance Change The Bull Case For BioCryst Pharmaceuticals (BCRX)?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/does-raised-2026-guidance-change-the-bull-case-for-biocryst
BioCryst Pharmaceuticals has raised its full-year 2026 revenue guidance to US$715 million to US$730 million, driven by strong performance from Orladeyo and increased international orders. This revised outlook, coupled with a profitable third quarter, supports the company's hereditary angioedema strategy, which relies on Orladeyo as a commercial engine and investigational navenibart as a potential second pillar. Upcoming presentations at the 2026 ACAAI meeting will provide further data on Orladeyo and navenibart, which could influence future catalysts and investor sentiment.
Advertisement

One investor reports 12.3 million BioCryst (BCRX) shares, with no sole voting power.

https://www.stocktitan.net/sec-filings/BCRX/schedule-13g-biocryst-pharmaceuticals-inc-passive-investment-disclosu-ba6de9ffe1f5.html
State Street Corporation has reported beneficial ownership of 12,294,412 common shares, or 4.8% of BioCryst Pharmaceuticals Inc. (BCRX). The filing indicates that State Street holds shared voting power over 11,692,962 shares and shared dispositive power over all 12,294,412 shares, with no sole voting or dispositive authority. This disclosure is a Schedule 13G filing, categorizing the holding as 5% or less.

Results: BioCryst Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/results-biocryst-pharmaceuticals-inc-exceeded-expectations-a
BioCryst Pharmaceuticals (NASDAQ: BCRX) reported strong third-quarter results, with revenues exceeding expectations by 8.8% to reach US$180m and a statutory profit of US$0.14 per share, 69% above analyst forecasts. Despite the positive Q3, analysts have maintained their revenue and EPS estimates for 2027, projecting a 23% decline in revenue to US$736.4m and US$0.68 EPS, suggesting no significant change in the business's long-term outlook. The consensus price target remained at US$20.55, but a wide spread in individual analyst targets indicates divergent views on the company's future performance.

Raised Outlook And Strong Quarter Could Change The Case For BioCryst Stock

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/raised-outlook-and-strong-quarter-could-change-the-case-for
BioCryst Pharmaceuticals has raised its full-year 2026 revenue guidance to US$715 million to US$730 million, driven by strong ORLADEYO demand. Despite reporting positive net income in Q3 2026, the company still faces a significant year-to-date net loss of US$605.5 million, highlighting the ongoing challenge of managing high costs and competitive pressures. The updated outlook puts ORLADEYO's performance in context of these financial hurdles, making execution on cost control and pipeline progress critical for future growth.

BioCryst Q3 2026 slides: HAE portfolio drives 70% profit jump

https://www.investing.com/news/company-news/biocryst-q3-2026-slides-hae-portfolio-drives-70-profit-jump-93CH-5000635
BioCryst Pharmaceuticals reported a 70% increase in non-GAAP operating profit to $87 million in Q3 2026, driven by its ORLADEYO franchise for hereditary angioedema (HAE). The company raised its full-year 2026 revenue guidance and is strategically expanding its HAE portfolio with navenibart, a potential second commercial asset, while also developing BCX17725 for Netherton syndrome. These initiatives are expected to fuel long-term revenue growth and margin expansion.

BCRX: ORLADEYO growth, stronger profitability, and pipeline catalysts position 2027 for expansion

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4451698:0-bcrx-orladeyo-growth-stronger-profitability-and-pipeline-catalysts-position-2027-for-expansion/
BioCryst Pharmaceuticals (BCRX) reported strong Q3 2026 results with ORLADEYO growth and higher adjusted profitability, partly due to a one-time CareMed inventory build. The company increased its total revenue guidance for 2026, and its 2027 outlook is supported by pipeline catalysts and cost savings. This analysis is based on the Q3 2026 audio transcript from November 4, 2026.
Advertisement

Two planned BioCryst talks will have live audio webcasts from London and Florida.

https://www.stocktitan.net/news/BCRX/bio-cryst-to-present-at-upcoming-investor-32wb3oyuxlge.html
BioCryst Pharmaceuticals is scheduled to present at two upcoming investor conferences: the Jefferies Global Healthcare Conference in London on November 18, 2026, and the 9th Annual Evercore Healthcare Conference in Coral Gables, Florida, on December 1, 2026. Live audio webcasts and replays of both presentations will be available through the Investors & Media section of BioCryst’s website. The company focuses on developing medicines for hereditary angioedema (HAE) and other rare diseases.

BioCryst (BCRX) Q3 2026 Earnings Call Transcript

https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/8651775/biocryst-bcrx-q3-2026-earnings-call-transcript/
BioCryst Pharmaceuticals reported strong Q3 2026 results, with total revenue up 13% year-over-year, driven by ORLADEYO sales and licensing revenue. The company increased its full-year total revenue guidance while maintaining ORLADEYO revenue guidance due to a one-time inventory build from a new pharmacy partner and ongoing transition. BioCryst also highlighted pipeline progress with navenibart and BCX17725, along with significant cost savings from site closures.

BioCryst Pharma Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62866289/biocryst-pharma-q3-2026-earnings-call-transcript
BioCryst Pharma reported strong third-quarter financial results for 2026, with ORLADEYO net revenue reaching $174.8 million, a 20% year-over-year increase excluding European revenue. The company launched ORLADEYO pellets for children and plans a 150 mg pellet formulation, while advancing pipeline candidates like Nevenibart and BCX17725 for Netherton syndrome. BioCryst also announced a strategic shift towards external innovation, supported by a new Scientific Advisory Board, and raised its total revenue guidance for 2026 to $715-$730 million.

BioCryst Reports Third Quarter 2026 Financial Results

https://www.globenewswire.com/news-release/2026/11/04/3395167/29446/en/biocryst-reports-third-quarter-2026-financial-results.html
BioCryst Pharmaceuticals reported strong third-quarter 2026 financial results, with total net revenue of $180.3 million and ORLADEYO net revenue of $174.8 million. The company maintained its full-year ORLADEYO revenue guidance while increasing total revenue guidance and improving non-GAAP operating expense guidance. Key business updates included the successful launch of ORLADEYO oral pellets for pediatric patients, FDA approval for use in adolescents and adults, and advancements in its pipeline programs, navenibart and BCX17725.

BioCryst stock trades ahead of November 4 results

https://www.ad-hoc-news.de/boerse/news/corporate-news/biocryst-stock-trades-ahead-of-november-4-results/70452834
BioCryst Pharmaceuticals' stock traded at EUR 7.57 in Berlin late Tuesday, November 3, 2026, ahead of its third-quarter 2026 results. The company is set to release its financial results and host a conference call on November 4. BioCryst focuses on developing oral and injectable therapies for hereditary angioedema and other rare diseases.
Advertisement

BioCryst Pharmaceuticals, Inc. (BO1.F) Seasonal returns chart - Yahoo Finance

https://sg.finance.yahoo.com/quote/BO1.F/seasonality/
This article from Yahoo Finance presents a seasonal returns chart for BioCryst Pharmaceuticals, Inc. (BO1.F), showing the average monthly price return from 2016 to 2026. It also provides current stock information, including the delayed quote, a note about their upcoming Q3 2026 earnings call, and related tickers.

BioCryst Pharmaceuticals, Inc. (BCRX) Seasonal returns chart

https://uk.finance.yahoo.com/quote/BCRX/seasonality/
This article displays a seasonal returns chart for BioCryst Pharmaceuticals, Inc. (BCRX), showing the average monthly price return from 2016 to 2026. It also provides current stock information, including real-time price, after-hours trading, and links to various financial data points for the company.

Will Oral Pellet Approval Change BioCryst Pharmaceuticals (BCRX) Narrative

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/will-oral-pellet-approval-change-biocryst-pharmaceuticals-bc
BioCryst Pharmaceuticals recently received FDA approval for a once-daily ORLADEYO oral pellet for hereditary angioedema (HAE) patients, offering an alternative to capsules. While this improves the commercial appeal and helps with patient adherence, it does not fundamentally alter the company's reliance on ORLADEYO in a competitive market. Analysts project significant revenue and earnings growth by 2029, though some cautious forecasts highlight competition risks.

BioCryst to present HAE therapy data at medical meeting

https://www.investing.com/news/company-news/biocryst-to-present-hae-therapy-data-at-medical-meeting-93CH-4982821
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced that four abstracts from its hereditary angioedema (HAE) portfolio have been accepted for presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting. The company will present clinical data and real-world outcomes for ORLADEYO (berotralstat), an oral prophylactic therapy for HAE, and long-term clinical trial outcomes for navenibart, an injectable monoclonal antibody for HAE attack prevention. The presentations will cover reductions in hospitalizations and emergency department visits, healthcare utilization, growth-related dose adjustments in children, and long-term safety and efficacy.

BioCryst to Present New Data for ORLADEYO® (berotralstat)

https://www.globenewswire.com/news-release/2026/10/29/3391103/29446/en/biocryst-to-present-new-data-for-orladeyo-berotralstat-and-navenibart-at-the-2026-american-college-of-allergy-asthma-immunology-annual-scientific-meeting.html
BioCryst Pharmaceuticals announced that it will present new clinical data and real-world outcomes for ORLADEYO® (berotralstat) and long-term clinical trial outcomes for navenibart at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting. The presentations will include data on hospitalization reductions, healthcare utilization among patients switching to berotralstat, dose adjustments in pediatric patients, and long-term safety and efficacy of navenibart for hereditary angioedema (HAE). These findings underscore BioCryst's commitment to advancing therapies for individuals with HAE.
Advertisement

BCRX Q3'26 Earnings: revenue estimate is 165.67M USD

https://www.tradingview.com/news/tradingview:f92c9395015fe:0-bcrx-q3-26-earnings-revenue-estimate-is-165-67m-usd/
BioCryst Pharmaceuticals, Inc. (BCRX) is scheduled to release its Q3'26 earnings on November 04, before market open. Analysts estimate the company will report revenue of $165.67 million and earnings per share (EPS) of $0.09 for the quarter. The article also provides a table summarizing past revenue and EPS figures, including reported and estimated values, and the surprise percentage.

BioCryst Pharmaceuticals, Inc. Estimates – NASDAQ:BCRX

https://www.tradingview.com/symbols/NASDAQ-BCRX/financials-estimates/
This page on TradingView provides financial estimates and actuals for BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates. The platform also allows visualization of financial trends over time for both annual and quarterly data.

BioCryst Pharmaceuticals, Inc. Estimates – BIVA:BCRX

https://www.tradingview.com/symbols/BIVA-BCRX/financials-estimates/
This article provides an overview of BioCryst Pharmaceuticals, Inc. (BCRX) financial data and analyst estimates on TradingView. It covers actual results versus average, high, and low estimates across income statement, balance sheet, cash flow, and valuation metrics. Users can explore trends over time for the company's financial performance.

FDA Clears Oral Pellets That Could Be A Game Changer For BioCryst Pharmaceuticals (BCRX)

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/fda-clears-oral-pellets-that-could-be-a-game-changer-for-bio
BioCryst Pharmaceuticals received FDA approval for a new 150 mg oral pellet formulation of ORLADEYO, an HAE prophylaxis treatment, offering an alternative to capsules. This development is expected to improve treatment adherence and prescribing flexibility, supporting the company's investment narrative focused on ORLADEYO's sustained role in the HAE market. Investors are now looking to the upcoming Q3 2026 earnings call for updates on commercial execution, patient additions, and the impact of the new formulation.

BioCryst Pharmaceuticals Q3FY26 Results: Earnings call set for Nov 4

https://scanx.trade/stock-market-news/companies/biocryst-pharmaceuticals-q3fy26-results-earnings-call-set-nov-4/54168267
BioCryst Pharmaceuticals will release its third-quarter 2026 financial results on November 4, 2026. The company will also host a conference call and webcast on the same day at 8:30 am ET to discuss the results and provide a corporate update. Details for the live webcast and replay will be available in the investors section of the company's website.
Advertisement

BioCryst to Report Third Quarter 2026 Financial Results on November 4

https://www.manilatimes.net/2026/10/22/tmt-newswire/globenewswire/biocryst-to-report-third-quarter-2026-financial-results-on-november-4/2451204/amp
BioCryst Pharmaceuticals, Inc. announced it will report its third quarter 2026 financial results on Wednesday, November 4, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. BioCryst is a global biotechnology company focusing on hereditary angioedema (HAE) and other rare diseases.

A live webcast will accompany BioCryst’s results call at 8:30 a.m. ET on Nov. 4.

https://www.stocktitan.net/news/BCRX/bio-cryst-to-report-third-quarter-2026-financial-results-on-november-u5uf2qey45gd.html
BioCryst Pharmaceuticals (BCRX) is scheduled to report its third-quarter 2026 financial results on Wednesday, November 4, 2026. Management will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss these results and provide a corporate update. A live webcast and replay will be accessible via the investors section of the company's website.

TD Cowen Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $30

https://www.moomoo.com/news/post/1001877861/td-cowen-maintains-biocryst-pharmaceuticals-bcrxus-with-buy-rating-maintains
TD Cowen analyst Stacy Ku has reiterated a Buy rating for BioCryst Pharmaceuticals (BCRX.US) and maintained a target price of $30. According to TipRanks data, the analyst has a 45.0% success rate and an average return of 2.7% over the past year. This rating comes as BCRX saw a -2.31% change, with the information provided by Moomoo News.

BioCryst to Report Third Quarter 2026 Financial Results on November 4

https://www.globenewswire.com/news-release/2026/10/21/3385876/29446/en/biocryst-to-report-third-quarter-2026-financial-results-on-november-4.html
BioCryst Pharmaceuticals, Inc. announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026. The company will host a conference call and webcast at 8:30 a.m. ET on that day to discuss the results and provide a corporate update. A replay of the call will be available online in the investors section of BioCryst's website.

BioCryst to Report Third Quarter 2026 Financial Results on November 4

https://www.globenewswire.com/news-release/2026/10/21/3385876/0/en/biocryst-to-report-third-quarter-2026-financial-results-on-november-4.html
BioCryst Pharmaceuticals, Inc. announced it will report its third-quarter 2026 financial results on Wednesday, November 4, 2026. The company will host a conference call and webcast at 8:30 a.m. ET on that day to discuss the results and provide a corporate update. A replay of the call will be available online in the investors section of the company's website.
Advertisement

BioCryst wins FDA approval for ORLADEYO pellet formulation By Investing.com

https://ng.investing.com/news/stock-market-news/biocryst-wins-fda-approval-for-orladeyo-pellet-formulation-93CH-2748182
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) has received FDA approval for its ORLADEYO oral pellet formulation, offering an alternative administration method for adults and adolescents aged 12 and older who have difficulty swallowing capsules. This new formulation can be taken with water or milk, or sprinkled on soft, non-acidic food. ORLADEYO is a prophylactic treatment for hereditary angioedema, with its capsule form previously demonstrating significant attack-rate reduction.

BioCryst wins FDA nod for Orladeyo oral pellets (BCRX:NASDAQ)

https://seekingalpha.com/news/4655236-biocryst-wins-fda-nod-orladeyo-oral-pellets
BioCryst Pharmaceuticals announced that the FDA has approved a new oral pellet formulation of its product, Orladeyo. This approval represents a label expansion for the once-daily therapy, which is used to treat hereditary angioedema, a rare genetic condition.

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

https://www.biospace.com/press-releases/biocryst-announces-u-s-fda-approval-of-orladeyo-150-mg-oral-pellets-for-adults-and-adolescents-with-hae
BioCryst Pharmaceuticals announced the U.S. FDA approval of ORLADEYO® (berotralstat) 150 mg oral pellets for prophylactic therapy in adults and adolescents aged 12 years and older with Hereditary Angioedema (HAE). This new pellet formulation provides an alternative administration option for patients who have difficulty swallowing or prefer not to take capsules. ORLADEYO is the first and only targeted oral prophylactic therapy for HAE patients aged 2 and above, offering proven efficacy in reducing HAE attacks.

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

https://www.globenewswire.com/news-release/2026/10/21/3385361/0/en/biocryst-announces-u-s-fda-approval-of-orladeyo-150-mg-oral-pellets-for-adults-and-adolescents-with-hae.html
BioCryst Pharmaceuticals announced the FDA approval of its ORLADEYO® 150 mg oral pellet formulation for adults and adolescents aged 12 and older with hereditary angioedema (HAE). This new option provides an alternative for patients who have difficulty swallowing capsules, expanding BioCryst's portfolio of targeted oral prophylactic therapies for HAE. ORLADEYO is now available in both capsule and pellet forms, offering flexibility to patients.

A daily medicine to prevent attacks from a hereditary swelling disorder now comes as pellets for people 12 and older.

https://www.stocktitan.net/news/BCRX/bio-cryst-announces-u-s-fda-approval-of-orladeyo-150-mg-oral-pellets-m2eyhx1ua8j7.html
BioCryst Pharmaceuticals received FDA approval for its 150 mg ORLADEYO oral pellets for the prophylactic treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 and older. This new formulation offers an alternative to capsules for patients who have difficulty swallowing or prefer pellets, expanding treatment options for HAE patients. The approval is based on safety and tolerability data, with previous capsule studies showing significant reductions in attack rates and rescue medication use.
Advertisement

BioCryst Pharmaceuticals wins FDA approval for 150 mg ORLADEYO pellets

https://mugglehead.com/biocryst-pharmaceuticals-fda-orladeyo-150-mg-pellets-approval/
BioCryst Pharmaceuticals has received FDA approval for 150 mg ORLADEYO oral pellets, offering an alternative to capsules for hereditary angioedema (HAE) patients aged 12 and older, especially those with swallowing difficulties. This new formulation broadens prevention options without adding a new age group to the drug's overall indication. While no launch date was provided, this approval is based on manufacturing information and safety data, as the company continues to generate substantial sales from ORLADEYO.

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

https://finance.yahoo.com/healthcare/articles/biocryst-announces-u-fda-approval-110000963.html
BioCryst Pharmaceuticals announced that the U.S. FDA has approved a supplemental New Drug Application for ORLADEYO® 150 mg oral pellets. This new formulation provides an alternative administration option for adults and adolescents aged 12 and older with hereditary angioedema (HAE) who may have difficulty swallowing capsules. ORLADEYO is the first and only targeted oral prophylactic therapy for HAE patients aged 2 and above, offering proven efficacy in preventing HAE attacks.

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

https://www.globenewswire.com/news-release/2026/10/21/3385361/29446/en/biocryst-announces-u-s-fda-approval-of-orladeyo-150-mg-oral-pellets-for-adults-and-adolescents-with-hae.html
BioCryst Pharmaceuticals, Inc. has announced the U.S. FDA approval of its ORLADEYO® 150 mg oral pellet formulation for the prophylactic treatment of hereditary angioedema (HAE) in adults and adolescents aged 12 and older. This new formulation offers an alternative for patients who have difficulty swallowing capsules, enhancing personalized treatment options. ORLADEYO is the first and only targeted oral prophylactic therapy for HAE patients aged 2 and above, with proven efficacy in reducing attack rates.

BioCryst Pharmaceuticals stock gains 2.32 percent at EUR 7.06

https://www.ad-hoc-news.de/boerse/news/nebenwerte/biocryst-pharmaceuticals-stock-gains-2-32-percent-at-eur-7-06/70377232
BioCryst Pharmaceuticals (BCRX) stock increased by 2.32 percent to EUR 7.06 on October 20, 2026, trading at Lang & Schwarz. This gain followed a robust second quarter where revenue hit USD 218.25 million, a 33.60 percent year-over-year increase, and net profit reached USD 78.40 million. The company is set to report its third-quarter results on November 2, 2026, with analysts anticipating continued revenue and earnings growth.

Wedbush Cuts Price Target on BioCryst Pharmaceuticals to $18 From $20, Keeps Outperform Rating

https://finance.yahoo.com/markets/stocks/articles/wedbush-cuts-price-target-biocryst-111132779.html
Wedbush has lowered its price target for BioCryst Pharmaceuticals (BCRX) to $18 from $20, while maintaining an "Outperform" rating on the stock. According to MT Newswires, the pharmaceutical company currently has an average rating of "buy" and a mean price target of $20.73. Access to the full article requires a premium subscription.
Advertisement

RBC keeps USD 11.00 target as BioCryst stock closed at USD 7.79 on October 16, 2026

https://www.ad-hoc-news.de/boerse/news/nebenwerte/rbc-keeps-usd-11-00-target-as-biocryst-stock-closed-at-usd-7-79-on-october-16-2026/70349760
RBC Capital has maintained its "Hold" rating and an $11.00 price target for BioCryst Pharmaceuticals, with the stock closing at $7.79 on October 16, 2026. The company is set to release its next earnings report on November 2, 2026, and its market capitalization stood at $2.0 billion. BioCryst, which develops oral medicines for rare diseases, traded within a 52-week range of $6.23 to $11.22.

Bank of America sets USD 15.00 target for BioCryst stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/bank-of-america-sets-usd-15-00-target-for-biocryst-stock/70332873
Bank of America Securities has set a USD 15.00 price target for BioCryst Pharmaceuticals (BCRX), representing an 86.34% upside from its recent Nasdaq price. This comes as BioCryst reported strong Q2 2026 revenues of USD 218.25 million, a 33.60% increase year-over-year, and significant net income growth. The company's stock is currently trading at EUR 7.20 on Lang & Schwarz, with its next earnings date estimated for November 2, 2026.

How New Advisory Board At BioCryst Pharmaceuticals (BCRX) Has Changed Its Investment Story

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/how-new-advisory-board-at-biocryst-pharmaceuticals-bcrx-has
BioCryst Pharmaceuticals recently established a seven-member Scientific Advisory Board to guide its pipeline expansion, translational science, and regulatory planning, particularly in rare disease R&D. This board aims to refine capital allocation for pipeline development and external deals, rather than immediately impacting sales, and is seen as crucial for BioCryst's transition from a single-product company to one with a multi-program portfolio. While the company faces significant current losses, analysts anticipate a substantial earnings swing and revenue growth by 2029, suggesting a potential upside influenced by the advisory board's impact on its development strategy.

BioCryst Pharmaceuticals, Inc. (BCRX) Options Chain

https://ca.finance.yahoo.com/quote/BCRX/options/?date=1797552000&straddle=false&type=all
This article provides the options chain information for BioCryst Pharmaceuticals, Inc. (BCRX) on Yahoo Finance. It displays real-time price data for BCRX, indicating a slight dip and overnight trading activity. The options chain, dated December 18, 2026, currently shows no available calls or puts.

BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $15

https://www.moomoo.com/news/post/1000835565/bofa-securities-maintains-biocryst-pharmaceuticals-bcrxus-with-buy-rating-maintains
BofA Securities has reiterated its Buy rating on BioCryst Pharmaceuticals (BCRX.US) and maintained its price target at $15. This indicates a continued positive outlook from the firm regarding the company's stock performance and valuation.
Advertisement

People on the Move: BioCryst Forms Scientific Advisory Board of Seven Rare Disease Leaders

https://biobuzz.io/news/people-on-the-move-biocryst-forms-scientific-advisory-board-of-seven-rare-disease-leaders/
BioCryst Pharmaceuticals, a global biotechnology company focused on rare diseases, has formed a new seven-member Scientific Advisory Board (SAB). The SAB comprises leaders in rare disease drug discovery and development, who will provide strategic guidance for BioCryst's R&D activities, pipeline expansion, and external innovation. This move supports BioCryst's strategy to enhance its R&D model centered on external innovation and strengthen its ties with scientific and medical communities.

RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Maintains Target Price $11

https://www.moomoo.com/news/post/1000803090/rbc-capital-maintains-biocryst-pharmaceuticals-bcrxus-with-hold-rating-maintains
RBC Capital has reiterated its Hold rating on BioCryst Pharmaceuticals (BCRX.US), maintaining a target price of $11. This indicates that RBC Capital views the company's stock as likely to perform in line with the broader market, with no expected significant upside or downside from its current valuation based on their analysis.

BioCryst stock trades 1.47 percent below its prior close ahead of results

https://www.ad-hoc-news.de/boerse/news/nebenwerte/biocryst-stock-trades-1-47-percent-below-its-prior-close-ahead-of-results/70269390
BioCryst Pharmaceuticals stock traded 1.47% lower at EUR 7.38 on October 8, 2026, ahead of its Q3 2026 earnings report scheduled for November 2, 2026. The company reported strong Q2 2026 results with revenue up 33.60% year over year to USD 218.25 million, and JPMorgan recently raised its price target for BioCryst to USD 13.00. Investors are now anticipating the upcoming Q3 report for further insights.

BioCryst Pharmaceuticals (BCRX) Names Scientific Advisory Board, Is The Discount Too Wide?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/biocryst-pharmaceuticals-bcrx-names-scientific-advisory-boar
BioCryst Pharmaceuticals (BCRX) has established a new Scientific Advisory Board, bringing fresh attention to its R&D pipeline. Despite recent stock pullbacks, longer-term returns suggest underlying momentum, and the company is trading significantly below its perceived fair value of $21.30 compared to its current $8.40. The company's future hinges on the continued success of ORLADEYO and the development of its early-stage assets, while investors weigh the market discount against execution risks and R&D opportunities.

BioCryst Pharmaceuticals stock gets USD 20.50 target as BioCryst forms board

https://www.ad-hoc-news.de/boerse/news/nebenwerte/biocryst-pharmaceuticals-stock-gets-usd-20-50-target-as-biocryst-forms-board/70250672
BioCryst Pharmaceuticals (BCRX) has formed a seven-member scientific advisory board, aiming to enhance its rare-disease pipeline through external innovation. The company's second-quarter 2026 revenue increased by 45% year-over-year to $218.25 million, largely due to ORLADEYO sales and a significant licensing payment. BioCryst has also raised its total revenue guidance for fiscal year 2026 to between $690 million and $715 million, while maintaining ORLADEYO-specific guidance.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement